SAR440894 / Sanofi - LARVOL DELTA

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Dec 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jun 2022 ➔ Dec 2023 | Trial primary completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Trial completion date: Feb 2022 ➔ Jun 2022; Trial primary completion date: Feb 2022 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Trial completion date: Oct 2022 ➔ Dec 2021; Trial primary completion date: Oct 2022 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Chikungunya • Infectious Disease

Phase 1 Study of SAR440894 vs Placebo (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Clinical • New P1 trial • Chikungunya